Acumen Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page)
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Daniel O’Connell, William Matthew Zuga and Derek Meisner, and each of them, as his or her true and lawful agents, proxies and attorneys-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities to sign this Annual Report on Form 10-K of Acumen Pharmaceuticals, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his substitutes, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Daniel O’Connell | Chief Executive Officer and Director | March 26, 2026 |
| Daniel O’Connell | (Principal Executive Officer) | |
| /s/ William Matthew Zuga | Chief Financial Officer and Chief Business Officer | March 26, 2026 |
| William Matthew Zuga | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Kimberlee C. Drapkin | Director | March 26, 2026 |
| Kimberlee C. Drapkin | ||
| /s/ Nathan B. Fountain | Director | March 26, 2026 |
| Nathan B. Fountain, M.D. | ||
| /s/ George Golumbeski | Director | March 26, 2026 |
| George Golumbeski, Ph.D. | ||
| /s/ Jeffrey L. Ives | Director | March 26, 2026 |
| Jeffrey L. Ives, Ph.D. | ||
| /s/ Derrell D. Porter | Director | March 26, 2026 |
| Derrell D. Porter, M.D. | ||
| /s/ Sean Stalfort | Director | March 26, 2026 |
| Sean Stalfort | ||
| /s/ Laura Stoppel | Director | March 26, 2026 |
| Laura Stoppel, Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.